Cargando…
Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
Flash glucose monitoring (FGM) and real-time continuous glucose monitoring (RT-CGM) are increasingly used in clinical practice, with improvements in HbA1c and time in range (TIR) reported in clinical studies. We aimed to evaluate the impact of FGM and RT-CGM use on glycaemic outcomes in adults with...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615559/ https://www.ncbi.nlm.nih.gov/pubmed/34821673 http://dx.doi.org/10.3390/bios11110457 |
_version_ | 1784604133718753280 |
---|---|
author | Lee, Kyuhan Gunasinghe, Shakthi Chapman, Alyson Findlow, Lynne A. Hyland, Jody Ohol, Sheetal Urwin, Andrea Rutter, Martin K. Schofield, Jonathan Thabit, Hood Leelarathna, Lalantha |
author_facet | Lee, Kyuhan Gunasinghe, Shakthi Chapman, Alyson Findlow, Lynne A. Hyland, Jody Ohol, Sheetal Urwin, Andrea Rutter, Martin K. Schofield, Jonathan Thabit, Hood Leelarathna, Lalantha |
author_sort | Lee, Kyuhan |
collection | PubMed |
description | Flash glucose monitoring (FGM) and real-time continuous glucose monitoring (RT-CGM) are increasingly used in clinical practice, with improvements in HbA1c and time in range (TIR) reported in clinical studies. We aimed to evaluate the impact of FGM and RT-CGM use on glycaemic outcomes in adults with type 1 diabetes (T1DM) under routine clinical care. We performed a retrospective data analysis from electronic outpatient records and proprietary web-based glucose monitoring platforms. We measured HbA1c (pre-sensor vs. on-sensor data) and sensor-based outcomes from the previous three months as per the international consensus on RT-CGM reporting guidelines. Amongst the 789 adults with T1DM, HbA1c level decreased from 61.0 (54.0, 71.0) mmol/mol to 57 (49, 65.8) mmol/mol in 561 people using FGM, and from 60.0 (50.0, 70.0) mmol/mol to 58.8 (50.3, 66.8) mmol/mol in 198 using RT-CGM (p < 0.001 for both). We found that 23% of FGM users and 32% of RT-CGM users achieved a time-in-range (TIR) (3.9 to 10 mmol/L) of >70%. For time-below-range (TBR) < 4 mmol/L, 70% of RT-CGM users and 58% of FGM users met international recommendations of <4%. Our data add to the growing body of evidence supporting the use of FGM and RT-CGM in T1DM. |
format | Online Article Text |
id | pubmed-8615559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86155592021-11-26 Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre Lee, Kyuhan Gunasinghe, Shakthi Chapman, Alyson Findlow, Lynne A. Hyland, Jody Ohol, Sheetal Urwin, Andrea Rutter, Martin K. Schofield, Jonathan Thabit, Hood Leelarathna, Lalantha Biosensors (Basel) Article Flash glucose monitoring (FGM) and real-time continuous glucose monitoring (RT-CGM) are increasingly used in clinical practice, with improvements in HbA1c and time in range (TIR) reported in clinical studies. We aimed to evaluate the impact of FGM and RT-CGM use on glycaemic outcomes in adults with type 1 diabetes (T1DM) under routine clinical care. We performed a retrospective data analysis from electronic outpatient records and proprietary web-based glucose monitoring platforms. We measured HbA1c (pre-sensor vs. on-sensor data) and sensor-based outcomes from the previous three months as per the international consensus on RT-CGM reporting guidelines. Amongst the 789 adults with T1DM, HbA1c level decreased from 61.0 (54.0, 71.0) mmol/mol to 57 (49, 65.8) mmol/mol in 561 people using FGM, and from 60.0 (50.0, 70.0) mmol/mol to 58.8 (50.3, 66.8) mmol/mol in 198 using RT-CGM (p < 0.001 for both). We found that 23% of FGM users and 32% of RT-CGM users achieved a time-in-range (TIR) (3.9 to 10 mmol/L) of >70%. For time-below-range (TBR) < 4 mmol/L, 70% of RT-CGM users and 58% of FGM users met international recommendations of <4%. Our data add to the growing body of evidence supporting the use of FGM and RT-CGM in T1DM. MDPI 2021-11-15 /pmc/articles/PMC8615559/ /pubmed/34821673 http://dx.doi.org/10.3390/bios11110457 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Kyuhan Gunasinghe, Shakthi Chapman, Alyson Findlow, Lynne A. Hyland, Jody Ohol, Sheetal Urwin, Andrea Rutter, Martin K. Schofield, Jonathan Thabit, Hood Leelarathna, Lalantha Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre |
title | Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre |
title_full | Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre |
title_fullStr | Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre |
title_full_unstemmed | Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre |
title_short | Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre |
title_sort | real-world outcomes of glucose sensor use in type 1 diabetes—findings from a large uk centre |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615559/ https://www.ncbi.nlm.nih.gov/pubmed/34821673 http://dx.doi.org/10.3390/bios11110457 |
work_keys_str_mv | AT leekyuhan realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT gunasingheshakthi realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT chapmanalyson realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT findlowlynnea realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT hylandjody realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT oholsheetal realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT urwinandrea realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT ruttermartink realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT schofieldjonathan realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT thabithood realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT leelarathnalalantha realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre |